Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price target from $35 to $40.
TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $44 to $51.
Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $44 t...
Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $40 to $41.
HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $4...
- SEC Filing
Exelixis (NASDAQ:EXEL) raises FY2025 sales outlook from $2.250 billion-$2.350 billion to $2.300 billion-$2.350 billion vs $2.32...
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.61 by 27....
